Literature DB >> 2416886

Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.

H Cramer, D Schaudt, K Rissler, D Strubel, J M Warter, F Kuntzmann.   

Abstract

The concentrations of somatostatin-like immunoreactivity (SLI) and substance-P-like immunoreactivity (SPLI) in lumbar spinal fluid of patients with senile dementia of the Alzheimer type (SDAT), multi-infarct syndrome, communicating hydrocephalus and control patients were determined by specific radio-immunoassay. Mean SLI and SPLI levels were significantly lower in an aged control patient group (mean age 83.5 +/- 5.6 years) than in an adult control patient group (mean age 30.8 +/- 10 years). In the latter group SPLI levels correlated negatively with age. Mean SLI levels decreased with deterioration in SDAT patients by up to 33% in late dementia. SPLI correlated with SLI in SDAT patients but was decreased significantly only in late dementia patients. Moderate and insignificant decreases of SLI were observed in patients with multi-infarct syndrome or communicating hydrocephalus. Analysis of SLI by gel-permeation chromatography revealed molecular heterogeneity of SLI. At least four peaks of SLI were eluted, two of which had apparent molecular weights of about 10,000 and 15,500, possibly representing somatostatin precursors. The ratio of SRIF to SLI of higher molecular weight was increased in patients with dementia compared to control patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2416886     DOI: 10.1007/bf00313833

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

1.  The regional distribution of somatostatin in the rat brain.

Authors:  M Brownstein; A Arimura; H Sato; A V Schally; J S Kizer
Journal:  Endocrinology       Date:  1975-06       Impact factor: 4.736

2.  Radioimmunoassay for GH-release inhibiting hormone.

Authors:  A Arimura; H Sato; D H Coy; A V Schally
Journal:  Proc Soc Exp Biol Med       Date:  1975-03

3.  SYMPTOMATIC OCCULT HYDROCEPHALUS WITH "NORMAL" CEREBROSPINAL-FLUID PRESSURE.A TREATABLE SYNDROME.

Authors:  R D ADAMS; C M FISHER; S HAKIM; R G OJEMANN; W H SWEET
Journal:  N Engl J Med       Date:  1965-07-15       Impact factor: 91.245

4.  Reduced lumbar CSF somatostatin levels in Alzheimer's disease.

Authors:  P L Wood; P Etienne; S Lal; S Gauthier; S Cajal; N P Nair
Journal:  Life Sci       Date:  1982-11-08       Impact factor: 5.037

5.  Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease.

Authors:  A J Cross; T J Crow; E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-10

6.  Effect of somatostatin (SRIF) and L-glutamate on neurons of the sensorimotor cortex in awake habituated rabbits.

Authors:  S Ioffe; V Havlicek; H Friesen; V Chernick
Journal:  Brain Res       Date:  1978-09-22       Impact factor: 3.252

7.  Effects of haloperidol on somatostatin-like immunoreactivity in the CSF of Schizophrenic patients.

Authors:  W F Gattaz; K Rissler; D Gattaz; H Cramer
Journal:  Psychiatry Res       Date:  1986-01       Impact factor: 3.222

8.  Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain.

Authors:  P L McGeer; E G McGeer; J Suzuki; C E Dolman; T Nagai
Journal:  Neurology       Date:  1984-06       Impact factor: 9.910

9.  Elevation of neuropeptide Y (NPY) in substantia innominata in Alzheimer's type dementia.

Authors:  J M Allen; I N Ferrier; G W Roberts; A J Cross; T E Adrian; T J Crow; S R Bloom
Journal:  J Neurol Sci       Date:  1984-06       Impact factor: 3.181

10.  Neuropeptide Y-like immunoreactivity in neuritic plaques of Alzheimer's disease.

Authors:  D Dawbarn; P C Emson
Journal:  Biochem Biophys Res Commun       Date:  1985-01-16       Impact factor: 3.575

View more
  8 in total

1.  CSF galanin and cognition after shunt surgery in normal pressure hydrocephalus.

Authors:  M Mataró; M A Poca; M Del Mar Matarín; R Catalan; J Sahuquillo; R Galard
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

2.  Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System.

Authors:  Alejandra N Martinez; Mario T Philipp
Journal:  J Neurol Neuromedicine       Date:  2016

3.  Comparison of DSIP- (delta sleep-inducing peptide) and P-DSIP-like (phosphorylated) immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type, multi-infarct syndrome, communicating hydrocephalus and Parkinson's disease.

Authors:  A Ernst; H Cramer; D Strubel; F Kuntzmann; G A Schoenenberger
Journal:  J Neurol       Date:  1987-10       Impact factor: 4.849

4.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

5.  Neurotransmitter markers in the cerebrospinal fluid of normal subjects. Effects of aging and other confounding factors.

Authors:  P Hartikainen; H Soininen; K J Reinikainen; J Sirviö; R Soikkeli; P J Riekkinen
Journal:  J Neural Transm Gen Sect       Date:  1991

Review 6.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

7.  Somatostatin cerebrospinal fluid levels in dementia.

Authors:  A Molins; R Catalán; J Sahuquillo; J M Castellanos; A Codina; R Galard
Journal:  J Neurol       Date:  1991-06       Impact factor: 4.849

8.  Substance P-like immunoreactivity and somatostatin-like immunoreactivity in the ventricular fluid of patients with chronic pain syndromes.

Authors:  S Jost; C Reuner; J Geiger; M Mohadjer; E Milios; H Cramer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.